Transition to Chronic Fibrosis in an Animal Model of Retinal Detachment With Features of Proliferative Vitreoretinopathy.

Journal Information

Full Title: Invest Ophthalmol Vis Sci

Abbreviation: Invest Ophthalmol Vis Sci

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Ophthalmology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Evidence found in paper:

"all rabbit sequencing data can be accessed at geo accession numbers gse217333."

Code Sharing
Evidence found in paper:

"Conflicts of Interest: For this project, MSS received sponsored research support from Bayer as part of a research collaboration of the Wilmer Eye Institute with Bayer. MSS is/was a paid advisor to Bayer Healthcare, Revision Therapeutics, Johnson & Johnson, Third Rock Ventures, Novartis Pharmaceuticals, W. L. Gore & Associates, Deerfield, Trinity Partners, Kala Pharmaceuticals, and Acucela. These arrangements have been reviewed and approved by the Johns Hopkins University in accordance with its conflict-of-interest policies. SB is a co-founder and Scientific Advisory Board member of CDI Labs, LLC, and is/was a paid advisor to Third Rock Ventures and Tenpoint Therapeutics. WS is a paid employee of Bayer Pharma AG. KN is a paid employee of Bayer Pharma AG. TZ is paid employee of Bayer Pharma AG. The remaining authors report no conflicts."

Evidence found in paper:

"Funded by Bayer AG as part of a sponsored research collaboration with the Wilmer Eye Institute, Johns Hopkins Hospital. Peterson's and Santiago's salary support was provided by NIH T32 OD011089 (PI: Mankowski) and NIH 2T32EY007143 (PI: Zack), respectively. Conflicts of Interest: For this project, MSS received sponsored research support from Bayer as part of a research collaboration of the Wilmer Eye Institute with Bayer. MSS is/was a paid advisor to Bayer Healthcare, Revision Therapeutics, Johnson & Johnson, Third Rock Ventures, Novartis Pharmaceuticals, W. L. Gore & Associates, Deerfield, Trinity Partners, Kala Pharmaceuticals, and Acucela. These arrangements have been reviewed and approved by the Johns Hopkins University in accordance with its conflict-of-interest policies. SB is a co-founder and Scientific Advisory Board member of CDI Labs, LLC, and is/was a paid advisor to Third Rock Ventures and Tenpoint Therapeutics. WS is a paid employee of Bayer Pharma AG. KN is a paid employee of Bayer Pharma AG. TZ is paid employee of Bayer Pharma AG. The remaining authors report no conflicts."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025